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Summary	
	
Haem	 oxygenase	 (HO)	 and	 its	 product	 carbon	monoxide	 (CO)	 are	 associated	with	
cytoprotection	 and	 maintenance	 of	 homeostasis	 in	 several	 distinct	 organs	 and	
tissues.	This	 review	 focuses	on	 the	 role	of	exogenous	and	endogenous	CO	 (via	HO	
activity	and	expression)	in	various	central	nervous	system	pathologies,	based	on	data	
from	experimental	models,	 as	well	 as	 from	 some	 clinical	 data	 on	 human	patients.	
The	 described	 and	 revised	 pathophysiological	 conditions	 are	 cerebral	 ischemia,	
chronic	 neurodegenerative	 diseases	 (Alzheimer	 and	 Parkinson	 diseases),	 multiple	
sclerosis	 and	 pain.	 Among	 these	 pathophysiological	 conditions,	 some	 cellular	
mechanisms	 and	 processes	 are	 considered,	 namely	 cytoprotection,	 cell	 death,	
inflammation,	cell	metabolism,	cellular	redox	responses	and	vasomodulation;	as	well	
as	the	different	targeted	neural	cells.	Finally,	novel	potential	methods	and	strategies	
for	delivering	exogenous	CO	as	a	drug	are	discussed,	in	particular	approaches	based	
on	 CO-releasing	 molecules,	 their	 limitations	 and	 challenges.	 The	 diagnostic	 and	
prognostic	value	of	haem	oxygenase	expression	in	clinical	use	for	brain	pathologies	is	
also	addressed.	
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ischemic	preconditioning;	HO	–	haem	oxygenase;	LPS	–	Lipopolysaccharide;	MCAO	–	middle	
cerebral	 artery	 occlusion;	 mitoKATP	 –	 ATP-dependent	 mitochondrial	 K	 channel;	 MPP	 -	 1-
methyl-4-phenylpyridinium;	MS	 –	multiple	 sclerosis;	 NO	 –	 nitric	 oxide;	 NOS	 –	 nitric	 oxide	
synthase;	 PD	 –	 Parkinson	 disease;	 PI3K	 -	 phosphatidyl	 inositol	 3-kinase;	 ROS	 –	 reactive	
oxygen	species;	sGC	–	soluble	guanylyl	cyclase;	TNF-α	-	tumour	necrosis	factor	alpha;	TNF-γ	-	
tumour	necrosis	factor	gamma	
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Historical	facts	
Carbon	monoxide	(CO)	is	commonly	considered	toxic	due	to	its	high	affinity	for	haem	
proteins,	 which	 can	 compromise	 oxygen	 delivery	 in	 tissues	 (via	 formation	 of	
carboxyhaemoglobin)	 (Bernard,	1857,	Haldane,	1895).	Claude	Bernard	was	the	first	
to	 publish	 an	 accurate	 description	 of	 the	 physiology	 of	 carbon	 monoxide	 (CO)	
poisoning	 (Bernard,	 1857).	 About	 one	 century	 later,	 CO	 was	 also	 described	 as	
cytotoxic	 for	 limiting	 oxidative	 phosphorylation	 in	 cells	 (via	 cytochrome	 c	 oxidase	
inhibition)	(Wainio	and	Greenless,	1960,	Savolainen	et	al.,	1980),	for	further	review	
(Piantadosi,	2002).		
Later,	CO	was	 recognized	as	an	endogenous	molecule	 in	1949	when	Sjöstrand	and	
colleagues	 identified	 this	 gas	 as	 a	 natural	metabolite	 in	 the	 exhaled	 air	 of	 healthy	
humans	(Sjostrand,	1949).	Nevertheless,	 it	was	only	 in	1968	that	CO	was	published	
as	product	of	the	haem	catabolism	through	haem	oxygenase	action	(Tenhunen	et	al.,	
1968).	 Indeed,	 this	gas	 is	 formed	by	haem-oxygenase	 (HO)	activity	 following	haem	
degradation,	along	with	free	iron	and	biliverdin	(Figure	1.).		
	
Insert	FIGURE	1	here 
	
In	 1988,	 Harbin	 and	 colleagues	 performed	 a	 study	 about	 the	 neurophysiological	
effect	 of	 CO	 exposure,	 concluding	 that	 acute	 and	 low	 level	 CO	 exposure	 was	 not	
neurotoxic	in	normal	healthy	men	(Harbin	et	al.,	1988).	In	1993	CO	was	accepted	as	
a	 signalling	molecule,	being	considered	a	neurotransmitter	 (Verma	et	al.,	1993).	 In	
the	beginning	of	the	new	millennium,	it	was	described	the	first	therapeutic	action	of	
CO,	as	vasomodulator	(Sammut	et	al.,	1998),	as	anti-inflammatory	(Otterbein	et	al.,	
2000)	 and	 as	 anti-apoptotic	 (Brouard	 et	 al.,	 2000).	 Since	 then	 several	 distinct	
applications	 of	 CO	 were	 explored,	 namely	 in	 organ	 transplantation,	 as	
cardioprotective,	anti-inflammatory	and	anti-apoptotic	molecule,	and	for	limiting	cell	
proliferation,	 in	 the	 particular	 case	 of	 atherosclerosis	 (for	 review	 (Motterlini	 and	
Otterbein,	2010)).	The	first	applied	patent	for	CO	use	in	Medicine	was	in	2003	(Yale	
University.	 WO03094932A1;	 2003),	 for	 further	 information	 on	 CO	 based	 patents	
please	see	(Zuckerbraun,	2008,	Bannenberg	and	Vieira,	2009).	
	
Haem	oxygenase	
HO	can	be	found	in	two	main	isoforms:	HO-1	or	inducible	and	HO-2	or	constitutive.	
Both	respond	to	stress	by	increasing	their	expression	or	activity,	respectively	(Ryter	
et	al.,	2006).	HO-3	has	been	found	only	in	the	rat	brain	(McCoubrey	et	al.,	1997),	but	
not	in	the	human.	HO	is	expressed/activated	in	response	to	a	wide	range	of	different	
cell	 stress	 stimuli,	 namely	 oxidative	 stress,	 hyperthermia,	 hypothermia,	 ischemia,	
hypoxia,	hyperoxia,	 inflammation	or	UV	 (Gozzelino	et	al.,	2010).	HO	plays	a	crucial	
role	on	the	redox	state	of	the	cell	and	is	crucial	for	cellular	maintenance	and	survival	
in	many	systems,	such	as	brain	(Dore,	2002),	heart	(Piantadosi	et	al.,	2008),	intestine	
 4 
(Nakao	et	al.,	2008),	liver	(Babu	et	al.,	2007)	and	lung	(Morse	et	al.,	2009).	The	HO-
induced	maintenance	of	both	 tissue	homeostasis	and	cytoprotection	 is	due	 to	 two	
main	 actions:	 (i)	 the	 removal	 of	 haem	 group	 (originated	 from	 dying	 cells	 or	 from	
haemoglobin	 following	 haemorrhage)	 and	 (ii)	 to	 the	 biological	 activity	 of	 HO	
products	(Grochot-Przeczek	et	al.,	2012).	It	is	worth	of	note	that	under	stress	haem-
proteins	 can	 release	 free	 haem,	 which	 in	 turns	 become	 a	 strong	 oxidant	 through	
Fenton	reaction,	therefore,	catabolism	of	free	haem	by	HO	is	crucial	for	maintaining	
tissue	homeostasis	and	cytoprotection,	for	review	(Gozzelino	et	al.,	2010).		
	
Haem	oxygenase	and	Central	Nervous	System	
In	the	brain,	basal	HO-1	expression	is	low,	while	under	stress	stimulation	it	increases	
in	neuronal,	 glial	 and	endothelial	 cells.	 Likewise,	 constitutive	expression	of	HO-2	 is	
mainly	 distributed	 in	 mammalian	 neuraxis,	 but	 its	 expression	 can	 also	 increase	
following	damaging	 stimuli	 (Schipper,	 2004b,	 Schipper,	 2004a),	 such	as	 in	hypoxic-
ischemic	 insult	 (Sutherland	 et	 al.,	 2009).	 In	 several	 brain	 pathologies	 haem	
oxygenase	 expression	 and	 activity	 can	 be	 involved	 in	 the	 modulation	 of	 disease	
development,	as	well	as	in	the	reestablishment	of	tissue	homeostasis.		
	
HO	levels	as	potential	biomarkers	in	the	central	nervous	system	(CNS)	
The	use	of	HO	protein	as	a	biomarker	 for	brain	damage	presents	some	 limitations.	
First,	 increased	 levels	 of	 HO-1	 in	 the	 human	 serum	 are	 not	 brain-specific	 and	 can	
indicate	systemic	inflammation	and/or	tissue	damage.	Secondly,	although	it	is	widely	
accepted	that	HO	expression	is	associated	with	neuroprotection,	glial	cytoprotection	
and	 anti-inflammatory	 events,	 HO	 responds	 to	 several	 different	 stress	 stimuli.	
Likewise,	HO	increased	expression	indicates	tissue	pathological	features.	Therefore,	
it	 is	 complex	 to	 distinguish	 the	 HO	 expression	 significance,	 namely	 whether	 it	
qualifies	 for	 a	 pathological	 biomarker	 or	 it	 represents	 a	 predictable	 value	 for	 a	
favourable	outcome.		
For	 example,	 the	 levels	 of	 HO-1	 in	 the	 cerebrospinal	 fluid	 of	 infants	 and	 children	
after	 severe	 traumatic	 brain	 injury	 are	 higher	 (Cousar	 et	 al.,	 2006).	 Likewise,	 the	
levels	 of	 HO-1	 protein	 is	 a	 promising	 serum	 biomarker	 for	 early	 detection	 of	
Alzheimer	 disease	 ,	 since	 they	 seem	 to	 increase	 in	 patients	 with	 AD	 and	 mild	
cognitive	 impairment	 (Mueller	 et	 al.,	 2010).	 An	 example	 showing	 that	HO-1	 levels	
can	 be	 used	 as	 a	 diagnostic	 and	 prognostic	 biomarker	 is	 during	 hypothermia	
treatment	following	haemorrhagic	brain	injury	in	a	rat	model	(Yao	et	al.,	2011).	The	
brain	cooling-induced	decrease	on	HO-1	expression	was	associated	to	an	attenuation	
of	oedema	formation	and	a	decrease	on	haem	concentration	(Yao	et	al.,	2011).	Thus,	
in	 these	 three	 cases,	 HO-1	 expression	 is	 associated	 with	 the	 development	 of	
pathology	 and	 can	 be	 used	 as	 a	 diagnostic	 biomarker.	 On	 the	 contrary,	 in	
experimental	models	of	 cardiovascular	diseases	and	cerebral	 ischemia	 lower	 levels	
or	deletion	of	HO-1	and	-2	expressions	are	related	with	a	worse	outcome	(see	next	
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sections).	 Therefore,	 enhanced	 expression	 of	 HO	 could	 be	 associated	 with	 a	
favourable	 outcome	 being	 a	 prognostic	 biomarker.	 In	 summary,	 HO-1	 and	 HO-2	
levels	 display	 a	 potential	 and	 promising	 diagnostic	 and	 prognostic	 value	 as	
biomarkers	in	humans,	although	further	studies	are	urgently	necessary.		
In	 the	 following	 sections,	 examples	 relating	 cerebral	 pathologies	 and	 haem	
oxygenase	are	described	in	a	systematic	way.	
	
Cerebrovascular	diseases:	ischemia	and	reperfusion	
Cerebral	ischemia	is	the	main	cause	of	brain	damage	and	the	3rd	cause	of	death	in	
western	societies.	In	adults	it	is	mainly	due	to	stroke,	whereas	in	infants	is	caused	by	
perinatal	complications,	in	particular	birth	asphyxia.	Cerebral	damage	is	the	result	of	
oxygen	and	tissue	energy	depletion,	 leading	to	acidosis,	exacerbated	 inflammation,	
glutamate	excitotoxicity,	oxidative	stress	and	ultimately	neural	cell	death	(Dirnagl	et	
al.,	2009).	
Increasing	 data	 indicate	 that	 HO-1	 activity	 is	 crucial	 for	 tissue	 protection	 and	
regeneration	following	cerebral	ischemia.	In	humans,	there	is	a	long-term	increase	in	
the	 expression	 of	 haem	 oxygenase-1	 following	 focal	 cerebral	 infarctions	 and	
traumatic	brain	 injury	 (Beschorner	et	al.,	2000).	On	the	contrary,	 in	a	 rat	model	of	
transient	 cerebral	 ischemia,	 reduction	 of	HO-1	 expression	 is	 associated	with	more	
severe	 neurodegeneration	 (Moreira	 et	 al.,	 2007).	 Protection	 in	 ischemic	
preconditioning	(IPC)	against	permanent	ischemic	brain	injury	is	dependent	on	HO-1	
expression,	 since	 IPC-promoted	neuroprotection	 is	abolished	 in	HO-1	gene	deleted	
mice	(Zeynalov	et	al.,	2009).	Likewise,	overexpression	of	HO-1	by	adenovirus	vector	
treatment	attenuated	brain	damage	after	focal	cerebral	ischemia	in	rats	(Chao	et	al.,	
2013).		
	
Modulation	of	cerebrovasodilation	by	haem-oxygenase	
In	neonates,	recurrent	seizures	may	result	 from	meningitis,	haemorrhage,	asphyxia	
and	 hypoxia	 or	 metabolic	 disorders.	 Neonatal	 seizures	 may	 promote	 neuronal	
damage	and	susceptibility	to	epilepsy	in	survivors.	Both	HO-1	and	HO-2	activities	in	
astrocytes,	neurons,	endothelial	 cells	and	smooth	muscle	cells	 (in	 cerebral	vessels)	
are	 involved	 in	 the	 modulation	 of	 cerebral	 blood	 flow	 and	 vasodilation	 during	
seizures	(Basuroy	et	al.,	2006,	Parfenova	et	al.,	2003,	Parfenova	et	al.,	2012a,	Xi	et	
al.,	 2011).	 Moreover,	 ionotropic	 glutamate	 receptors	 mediate	 HO	 activation	 and	
endogenous	production	of	CO,	which	 increases	cerebral	blood	flow	for	maintaining	
brain	homeostasis	and	neuronal	survival	during	seizures	(Parfenova	et	al.,	2012b).	
	
Heme	oxygenase	and	Alzheimer	disease	
Despite	 the	 increasing	 amount	 of	 data	 demonstrating	 haem	 oxygenase	 as	 a	
widespread	 cytoprotective	 enzyme,	 its	 homeostatic	 and	 neuroprotective	 role	 in	
Alzheimer	disease	(AD)	is	somewhat	controversial.	AD	is	associated	with	an	increase	
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deposition	 of	 redox-active	 iron,	 chronic	 oxidative	 stress	 and	 mitochondrial	
malfunctioning,	 which	 are	 implicated	 in	 the	 development	 of	 this	 pathological	
disorder.	Indeed,	in	experimental	models,	glial	overexpression	of	haem	oxygenase-1	
promoted	 mitochondrial	 oxidative	 stress	 (Song	 et	 al.,	 2006)	 and	 mediated	
mitochondrial	membrane	damage	and	autophagy	in	astrocytes	(Zukor	et	al.,	2009).	
Additionally,	 in	mouse	 brain,	 long-term	 overexpression	 of	 HO-1	 induced	 toxic	 tau	
accumulation	 (Hui	 et	 al.,	 2011)	 and	 increased	 deposits	 of	 glial	 iron	 (Song	 et	 al.,	
2012).		
On	 the	 contrary,	 HO	 expression	 appears	 to	 be	 involved	 in	 reduction	 of	 brain	
oxidative	stress.	In	an	aging	canine	model,	which	develops	cognitive	dysfunction	and	
neuropathology	 similar	 to	 those	 in	 human	 AD	 patients,	 atovastatin-induced	 up-
regulation	of	HO	is	associated	with	reduced	oxidative	stress	(Butterfield	et	al.,	2012).	
In	 the	 same	 canine	model,	 brain	 oxidative	 stress	 biomarkers	 (protein	 carbonyl,	 3-
nitrotyrosine	and	levels	of	products	of	lipid	peroxidation)	were	attenuated	following	
enriched	 environment-antioxidant-fortified	 feeding,	 which	 was	 strongly	 associated	
with	an	enhancement	of	HO-1	protein	levels	(Opii	et	al.,	2008).		
HO	 suppressor	 factors,	 such	 as	 α1-antitrypsin,	 may	 also	 play	 a	 role	 in	 the	
development	of	AD,	since	Maes	and	colleagues	have	found	significantly	augmented	
plasma	HO	suppressor	activity	 in	AD	patients	 relative	 to	healthy	elderlies	 (Maes	et	
al.,	2006).	
As	 previously	 mentioned,	 HO	 levels	 increased	 in	 serum	 of	 AD	 patients,	 being	 a	
potential	 diagnostic	 biomarker	 (Mueller	 et	 al.,	 2010).	 In	 addition,	 HO	
posttranslational	 modification	 might	 also	 be	 involved	 in	 the	 development	 of	 AD.	
Barone	and	colleagues	(2012)	have	found	that	HO-1	protein	levels	were	significantly	
increased	 in	 the	 hippocampus	 of	 AD	 subjects,	 whereas	 HO-2	 protein	 levels	 were	
significantly	decreased	 in	both	AD	and	mild	cognitive	 impairment	hippocampi.	Ser-
residue	phosphorylation	 and	 increased	oxidative	 posttranslational	modifications	 of	
HO-1	 were	 also	 found	 in	 the	 hippocampus	 of	 AD	 subjects	 (Barone	 et	 al.,	 2012).		
Controversially,	 it	 was	 also	 observed	 that	 HO-1	 protein	 levels	 are	 lower	 in	 post-
mortem	specimens	of	cerebrospinal	fluid	reviewed	in	(Schipper,	2000).		
	Thus,	HO	isoforms	and	protein	posttranslational	modifications	might	also	play	a	role	
in	the	debate	between	neuroprotective	vs	neurotoxic	effects	of	HO	activity	in	AD.	
	
Heme	oxygenase	and	Parkinson	disease	
Oxidative	 stress,	 accumulation	 of	 Lewy	 bodies	 and	 decrease	 of	 mitochondrial	
complex	 I	 activity	 are	 common	 features	 occurring	 in	 nigral	 dopaminergic	 neurons	
(DN)	 during	 pathological	 development	 of	 Parkinson	 disease	 (PD).	 In	 postmortem	
human	 brain	 specimens	 collected	 from	 PD,	 immunohistochemistry	 was	 used	 to	
assess	HO-1	expression.	 In	 the	 substantia	nigra	of	both	PD	and	control	 specimens,	
moderate	 HO-1	 immunoreactivity	 was	 consistently	 observed	 in	 dopaminergic	
neurons,	 while	 the	 fraction	 of	 GFAP-positive	 astroglia	 expressing	 HO-1	 in	 PD	
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substantia	 nigra	 was	 significantly	 greater	 in	 PD	 patients	 (Schipper	 et	 al.,	 1998).	
Likewise,	 expression	 of	 HO-1	 measured	 by	 microarray	 analysis	 was	 enhanced	
following	 oxidative	 stress	 in	 dopaminergic	 neurons	 (Yoo	 et	 al.,	 2003).	 Despite	 the	
association	 of	 HO-1	 expression	 with	 PD	 development,	 HO-1	 activity	 emerges	 as	
involved	 with	 neuroprotection.	 For	 instance,	 in	 a	 rat	 model	 of	 MPP	 (1-methyl-4-
phenylpyridinium)-induced	PD,	local	injection	of	adenovirus	containing	human	HO-1	
gene	 increased	 the	 survival	 rate	 of	 dopaminergic	 neurons	 and	 reduced	 the	
production	 of	 tumour	 necrosis	 factor	 alpha	 (Hung	 et	 al.,	 2008).	 Using	 an	 in	 vitro	
model	of	rat	midbrain	slice	culture,	in	which	dopaminergic	neurons	were	induced	to	
die	 by	 INF-gamma/LPS	 treatment,	 surviving	 neurons	 displayed	 more	 robust	
expression	of	HO-1	whereas	treatment	with	HO-1	 inhibitor,	zinc	protoporphyrin	 IX,	
increased	cell	death	levels	(Kurauchi	et	al.,	2009).	Fibroblast	growth	factor	9	(FBF9)	
prevented	 MPP-induced	 nigral	 dopaminergic	 neuronal	 death	 via	 up-regulation	 of	
HO-1	 (Huang	 and	 Chuang,	 2010).	 In	 the	 autosomal	 recessive	 form	 of	 PD,	 due	 to	
PINK1	G309D	mutation,	 there	 is	an	 impairment	of	HO-1	production	 in	 response	 to	
oxidative	 stress	 (Chien	 et	 al.,	 2011).	 In	 addition,	 HO-1	 activity	 also	 seems	 to	 be	
associated	with	modulation	of	proteasome	degradation,	whose	activity	is	decreased	
in	 patients	 with	 PD.	 Indeed,	 misfolding	 proteins	 promote	 neuronal	 toxic	 stimuli,	
which	 induce	 HO-1	 expression,	 and,	 in	 turn,	 prevent	 intracellular	 accumulation	 of	
protein	 aggregates	 and	 inclusions	 in	human	neuroblastoma	M17	 cells	 (Song	et	 al.,	
2009).	 Controversially,	 HO-1	 knockout	 mice	 submitted	 to	 MPP	 intraperitoneal	
injection	 for	 inducing	PD	presented	 the	 same	 levels	of	dopaminergic	degeneration	
and	severity	of	gliosis	as	control	animals	(Innamorato	et	al.,	2010).	
In	 summary,	 although	 HO	 activity	 is	 associated	 with	 cytoprotection	 and	
neuroprotection,	some	authors	have	suggested	that	it	is	implicated	in	neurotoxicity	
and	should	be	a	therapeutic	target	for	chronic	neurodegenerative	diseases	(AD	and	
PD),	 namely	 through	 the	 prevention	 of	 its	 expression	 and/or	 activity	 for	 avoiding	
iron	accumulation.	Indeed,	Schipper	and	colleagues	have	suggested	the	suppression	
of	glial	HO-1	activity	as	a	potential	therapeutic	strategy	for	treating	AD	(Schipper	et	
al.,	 2009).	 Furthermore,	 the	 levels	 of	 ferritin	 protein	 are	 crucial	 for	maintaining	 a	
functional	 cellular	 iron-storage,	 whose	 role	 must	 be	 coupled	 with	 HO	 activity.		
Ferritin	is	a	very	important	protein	with	a	dual	role	of	protecting	the	cell	against	the	
oxidative	 stress	 caused	 by	 free	 iron,	 yet	 allowing	 the	 access	 to	 it.	 There	 are	 two	
isoforms,	L	and	H,	distributed	 throughout	 the	 tissues.	L-ferritin	has	 iron	nucleation	
properties	and	a	mutation	on	this	chain	leads	to	iron	deposition	in	cerebellum,	basal	
ganglia	 and	 motor	 cortex,	 causing	 an	 autosomal	 dominant	 inherited	 disorder	
(neuroferritinopathy)	(Lehn	et	al.,	2012).	Additionally,	H-ferritin	mutations	lead	to	a	
propensity	to	oxidative	stress,	however	normal	 iron	concentration,	as	 the	L-ferritin	
compensates	the	loss	of	H-ferritin.	Thus,	one	can	also	speculate	that	depending	on	
the	ferritin	levels	and	activity,	HO	could	promote	cytoprotection	or	exacerbation	of	
damage.	 Indeed,	Thompson	and	colleagues	have	generated	a	mouse	model	 for	AD	
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and	PD,	based	on	a	deficiency	on	H-ferritin,	reinforcing	the	malicious	role	of	iron	in	
neurodegenerative	diseases	(Thompson	et	al.,	2003).	Another	important	discovery	is	
the	 existence	 of	mitochondrial	 ferritin,	which	 is	 expressed	 only	 in	 testis	 and	 brain	
(Yang	et	al.,	2013).	Despite	the	 lack	of	data	until	 this	date,	mitochondrial	 ferritin	 is	
considered	to	be	associated	with	neuroprotection	against	neurodegeneration	in	PD	
and	AD.	Thus,	HO	effect	on	neurodegenerative	diseases	must	be	studied	conjointly	
with	ferritin	activity.	
	
Neuroinflammation	and	multiple	sclerosis	
During	 the	 last	 decade,	 several	 data	 in	 the	 literature	 have	 demonstrated	 that	 HO	
activity	 can	also	modulate	neuroinflammation.	HO-1	appears	 to	be	 involved	 in	 the	
modulation	of	neuroinflammation	because	whenever	its	transcription	factor	Nrf-2	is	
knocked	out	mice	are	hypersensitive	to	LPS-induced	neuroinflammation	(Innamorato	
et	 al.,	 2008).	 Still,	 molecules	 exerting	 anti-neuroinflammatory	 effects,	 such	 as	
dimethyl	 fumarate	 (Lin	et	al.,	2011),	cyclopentenone	prostaglandins	 (Zhuang	et	al.,	
2003b)	 and	 6,4'-Dihydroxy-7-methoxyflavanone	 (Li	 et	 al.,	 2012)	 act	 through	
increasing	expression	of	HO-1.	
Multiple	 sclerosis	 (MS)	 is	 an	autoimmune	disease	affecting	CNS	with	 inflammatory	
lesions,	 demyelination	 and	 axonal	 loss	 (Fagone	 et	 al.,	 2012).	 In	 2001	 it	 was	 first	
shown	the	protective	and	anti-inflammatory	role	of	HO-1	activity	in	an	experimental	
model	of	multiple	sclerosis,	the	experimental	autoimmune	encephalomyelitis	(EAE).	
Pharmacological	 induction	 of	 HO-1	 with	 haemin	 effectively	 inhibited	 EAE,	 while	
prevention	 of	 HO-1	 activity	 with	 tin	 mesoporphyrin	 exacerbated	 EAE	 (Liu	 et	 al.,	
2001).	 Later	 the	 same	effect	was	demonstrated	by	genetic	 inhibition	of	HO-1,	EAE	
induction	 in	 HO-1	 knockout	 mice	 enhanced	 CNS	 demyelination,	 paralysis	 and	
mortality	 (Chora	et	al.,	2007).	Likewise,	multiple	sclerosis	patients	present	reduced	
levels	 of	 HO-1	 expression	 in	 peripheral	 blood	 mononuclear	 cells,	 and	 during	 the	
exacerbation	 of	 the	 disease	 there	 is	 a	 significant	 down	 regulation	 of	 this	 enzyme	
(Fagone	 et	 al.,	 2013).	 In	 contrast,	 there	 are	 also	 some	 works	 stating	 that	 over-
expression	 of	 HO-1	 in	 glial	 cells	 was	 toxic	 by	 promoting	 mitochondrial	 oxidative	
stress	and	damage	due	to	free	iron	accumulation	(Mehindate	et	al.,	2001),	and	this	
effect	could	be	reverted	by	the	addition	of	iron	chelator	deferoxamine	(Song	et	al.,	
2006).	Likewise,	in	astrocytes	of	spinal	cord	from	MS	patient	expressed	higher	levels	
of	HO-1	than	astrocytes	from	control	subjects	(Mehindate	et	al.,	2001).	
	
Pain	
Carvalho	and	colleagues	(2011)	proposed	the	HO-CO-cGMP	pathway	to	be	involved	
in	 the	 nociception	 caused	 by	 an	 acute	 painful	 stimulus	without	 inflammation.	 The	
administration	 of	 pharmacological	 inhibitor	 or	 substrate	 of	 HO	 and	 sGC	 inhibitor	
have	 shown	 that	 the	 anti-nociceptive	 action	 is	 reduced	 whenever	 HO	 activity	 is	
prevented,	being	this	effect	dependent	on	sGC	(Carvalho	et	al.,	2011).	
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Heme	oxygenase	in	neuroprotection	induced	by	naturally-occurring	compounds	
Epidemiological	 studies	 have	 revealed	 a	 reduced	 incidence	 of	 cardiovascular	 and	
neurodegeneration	 risk	 associated	 with	 consumers	 of	 specific	 foods,	 such	 berry	
fruits,	 red	wine,	 etc.	 Furthermore,	 a	wide	 variety	 of	 natural	 compounds	 extracted	
from	plants	or	fruits	are	claimed	to	promote	neuroprotection	through	modulation	of	
HO-1	 expression	 and/or	 activity.	 In	 2002	 it	was	 firstly	 described	 that	 in	 astrocytes	
curcumin	 induces	 HO-1	 expression	 and	 activity	 in	 a	 glutathione-independent	 way	
(Scapagnini	et	al.,	2002),	since	then	several	publications	have	shown	in	cell	culture	of	
neurons	and	astrocytes	 curcumin	protects	 against	 inflammation,	oxidative	damage	
and	 cell	 death	 (Table	 1).	 Ginkgo	 biloba,	 which	 is	 an	 extract	 used	 in	 traditional	
Chinese	medicine,	has	been	wildly	described	as	neuroprotective	compound.	In	Table	
1	 there	 are	 several	 examples	 showing	 HO	 implication	 in	 Ginkgo	 biloba-induced	
neuroprotection	using	in	vitro	and	in	vivo	models.	Resveratrol,	which	is	a	component	
of	red	wine	associated	to	cardioprotection	and	neuroprotection,	was	demonstrated	
to	confer	its	healthy	properties	by	HO-1	activation	in	vitro	and	in	vivo	(Sakata	et	al.,	
2010,	 Zhuang	 et	 al.,	 2003a),	 (Ren	 et	 al.,	 2011).	 Finally,	 other	 natural	 occurring	
compounds	 such	 as	 Flavanol(-)-epicatechin,	 Sevoflurane,	 Triterpenoid	 and	
Octreotide	are	also	implicated	in	neuroprotection	via	HO-1	activation	(Table	1).		
	
Carbon	monoxide	and	carbon	monoxide	releasing	molecules	(CORMs)	
During	the	last	two	decades,	many	CO	biological	functions	have	been	described	and	
a	great	effort	is	under	progress	for	developing	its	use	in	human	health.	The	potential	
clinical	 application	 of	 inhaled	 carbon	monoxide	 presents	 several	 disadvantages:	 (i)	
inhaled	CO	is	not	tissue	specific;	(ii)	CO	gas	is,	at	least	partially,	delivered	in	the	body	
through	 blood	 plasma	 flow	 and	 carboxyhaemoglobin,	 leading	 to	 partial	 systemic	
hypoxia	and	toxicity	and	(iii)	the	need	of	hospital	facilities	with	technical	devices	for	
CO	 inhalation	 and	monitoring	 oxygen	blood	 levels.	 To	 overcome	 these	 limitations,	
great	 efforts	 have	 been	 taken	 by	 chemists	 to	 create	 pro-drugs	 by	 synthesising	
molecules	 able	 to	 deliver	 CO,	 which	 were	 first	 denominated	 as	 carbon	monoxide	
releasing	 molecules	 –	 CORMs	 (Motterlini	 et	 al.,	 2002).	 Although	 an	 enormous	
number	of	CORMs	was	developed	in	the	last	decade,	only	few	of	them	have	shown	
proven	 and	 efficient	 beneficial	 biological	 effects	 in	 in	 vivo	 and	 in	 vitro	 systems.	
Several	 issued	 must	 be	 overcame	 in	 the	 development	 of	 CORMs,	 namely:	 water-
insolubility,	 toxic	 chemical	 structures,	 promotion	 of	 high	 levels	 of	
carboxyhaemoglobin,	 chemical	 instability,	 etc;	 for	 further	 review	 on	 the	 their	
development	(Romao	et	al.,	2012).	In	the	particular	case	of	central	nervous	system,	
the	 most	 studied	 pro-drugs	 were	 CORM-A1,	 CORM-2	 and	 CORM-3.	 CORM-A1	
([H3BCO2]Na2)	 is	 a	 boranocarbonate	 molecule;	 while	 the	 transition	 metal	 based	
molecules	are:	CORM-2	[Ru(CO)3Cl2]2,	which	 is	a	dimer	and	 insoluble	 in	water;	and	
the	water	soluble	CORM-3	([Ru(CO)3Cl(κ2-H2NCH2CO2)]).	Furthermore,	in	the	specific	
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case	of	experimental	cerebral	malaria,	a	new	ruthenium	based	molecule	was	tested	-	
ALF	 492,	 presenting	 CORM-3	 structure	 with	 methylthiogalactopyranoside	 ligand	
(Pena	 et	 al.,	 2012).	 Still,	molybdenum	 based	water-soluble	molecule	 ALF	 186	was	
shown	to	confer	neuroprotection	(Schallner	et	al.,	2013).	
Developing	 drugs	 for	 brain	 pathologies	 is	 highly	 challenging	 due	 to	 its	 extreme	
importance	 and	 complexity,	 as	well	 as	 due	 to	 the	 presence	 of	 blood	 brain	 barrier	
(BBB)	-	a	biological	barrier	constituted	by	the	endothelial	cells	of	the	blood	capillaries	
together	 with	 associated	 astrocytic	 end-feet	 processes	 and	 perivascular	 neurons.	
BBB	isolates	the	brain	and	decreases	the	risk	of	infection	and	the	entrance	of	toxins.	
Despite	the	amount	of	research	work	done	about	CORM	and	the	brain,	it	is	not	fully	
clarified	the	ability	of	any	CORM	to	cross	the	BBB;	while	 it	 is	accepted	that	CO	gas	
can	cross	biological	membranes.	
	
CO	and	Central	Nervous	System		
Exogenous	administration	of	low	levels	of	carbon	monoxide	(CO	gas	and	CORMs)	has	
been	 explored	 as	 potential	 therapeutic	 factor	 in	 many	 different	 models	 of	 brain	
pathologies,	which	are	described	in	this	section.	
	
Cerebrovascular	disease	
	
Low	levels	of	inhaled	CO	were	beneficial	against	cerebral	hypoxic	and	ischemic	insult	
in	 experimental	 rodent	 models.	 In	 mice,	 CO	 exposure	 at	 250	 ppm	 for	 18h	
immediately	after	permanent	middle	cerebral	artery	occlusion	(MCAO)	decreased	by	
about	 30%	 the	 infarct	 volume,	 after	 7	 days	 (Wang	 et	 al.,	 2011).	 Likewise,	 in	 a	
transient	MCAO	model	(90	minutes	of	focal	ischemia	followed	by	48h	of	reperfusion)	
inhalation	of	125	ppm	of	CO	immediately	at	the	onset	of	reperfusion	also	decreased	
about	30%	the	brain	damage	after	48h.	While,	 inhalation	of	CO	at	250	ppm	 in	 the	
same	model	and	conditions	decreased	around	60%	the	brain	damage.	Interestingly,	
when	 the	 CO	 inhalation	 is	 performed	 1h	 or	 3h	 after	 the	 reperfusion,	 there	 is	 still	
reduction	in	brain	damage,	by	70%	and	30%,	respectively	(Zeynalov	and	Dore,	2009).	
In	a	rat	model	of	haemorrhagic	stroke,	whenever	CORM-3	is	administered	5	minutes	
before	 or	 3	 days	 after	 the	 intracerebral	 haemorrhage	 stimulus	 (injection	 of	
collagenase),	decreased	the	inflammatory	response.	The	opposite	effect	is	achieved	
when	 CORM-3	 is	 injected	 3h	 after	 the	 haemorrhagic	 insult	 (Yabluchanskiy	 et	 al.,	
2012).	 Thus,	 the	 time	 window	 for	 CO	 administration	 is	 crucial	 for	 its	 biological	
functions	 and	 further	 studies	 are	 urgently	 necessary.	 In	 a	 perinatal	 rat	 model	 of	
cerebral	hypoxia-ischemia,	CO	exposure	at	250	ppm	for	1h/day	on	the	3	days	prior	
to	 the	 ischemic	 insult	decreased	64%	 the	apoptotic	 cell	death	 in	 the	hippocampus	
(Queiroga	et	al.,	2012b).	In	another	perinatal	experimental	system,	a	piglet	model	of	
deep	 hypothermic	 circulatory	 arrest	 (DHCA),	 mimicking	 the	 open-heart	 surgeries	
procedures,	 inhalation	 of	 280	 ppm	 CO,	 for	 3h,	 1	 day	 prior	 to	 surgery	 limited	 cell	
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death	in	the	neocortex	and	hippocampus	(Mahan	et	al.,	2012).	In	the	in	vivo	retinal	
ganglion	cells	model	of	ischemia	and	reperfusion,	CO	gas	preconditioning	(Biermann	
et	 al.,	 2010)	 and	 postconditioning	 (Schallner	 et	 al.,	 2012)	 also	 promoted	
neuroprotection.	 Finally,	 CORM-A1	 (2	 mg/kg,	 intraperitoneally)	 administration	 30	
minutes	before	seizure	chemical	induction	protects	against	seizure-induced	neonatal	
vascular	 injury	 in	 newborn	 piglets	 (Zimmermann	 et	 al.,	 2007,	 Parfenova	 et	 al.,	
2012a).	
	
Multiple	sclerosis		
In	the	established	model	of	MS,	experimental	autoimmune	encephalomyelitis	(EAE)	
in	 SJL	 mice,	 a	 prolonged	 prophylactic	 treatment	 with	 CORM-A1	 reduces	 the	
incidence	of	the	disease	and	attenuates	the	 inflammatory	 infiltrations	of	the	spinal	
cords	 (Fagone	 et	 al.,	 2011).	 Exogenous	 CO	 administration	 (250	 ppm)	 suppressed	
myelin-reactive	 immune	 cells	 activation	 within	 the	 CNS,	 contributing	 to	 the	
reduction	of	autoimmune	neuroinflammation	impairment	(Chora	et	al.,	2007).	
	
Pain	
Pain	 is	 another	 aspect	where	CO	has	 the	potential	 of	 improving	 patient	 quality	 of	
life.	Hervera	and	colleagues	have	demonstrated	that	treating	mice	with	CORM-2	and	
CORM-3	 for	 10	 to	 20	 days	 following	 sciatic	 nerve	 injury	 improved	 the	 local	 anti-
nociceptive	effects	of	morphine	and	significantly	reduced	the	main	neuropathic	pain	
symptoms,	 in	a	 time-dependent	manner.	Furthermore,	 this	CO	effect	 is	due	to	 the	
reduction	of	spinal	microglial	activation	and	NOS1/NOS2	over-expression	(Hervera	et	
al.,	2012,	Hervera	et	al.,	2013b,	Hervera	et	al.,	2013a).		
	
Brain	cells	and	carbon	monoxide:	in	vitro	approaches	
Cellular	consequences	of	ischemia,	such	as	excitotoxicity	and	oxidative	stress,	induce	
cell	 death	 and	 can	 be	mimicked	 in	 vitro.	 In	 primary	 culture	 of	 cerebellar	 granular	
neurons,	CO	gas	 limited	neuronal	 cell	death	via	 ROS	 signalling	and	acting	on	nitric	
oxide	 synthase	 (NOS),	 soluble	 guanylyl	 cyclase	 (sGC)	 and	 ATP-dependent	
mitochondrial	 K	 channel	 (mitoKATP)	 (Vieira	 et	 al.,	 2008).	 Similarly,	 CO-induced	
neuroprotection	was	 shown	 to	be	dependent	on	 sGC	activity	 and	 cyclic	 guanosine	
monophosphate	 (cGMP)	 production	 in	 SH-SY5Y	 neuronal	 cell	 line	 and	 in	 retinal	
ganglion	cells,	by	using	a	novel	CORM:	ALF	186	(Schallner	et	al.,	2013).		
Neuroprotection	 is	 not	 an	 exclusive	 matter	 of	 neuronal	 functioning.	 Indeed,	 one	
must	also	target	glial	cells	for	promoting	neuroprotection.	The	physiological	role	of	
astrocyte,	microglia,	 oligodendrocytes	 and	 endothelial	 cells	 is	 the	maintenance	 of	
brain	homeostasis,	metabolism	and	neuronal	functioning.	Therefore,	modulation	of	
glial	 cells	 functioning	 is	 crucial	 for	promoting	neuroprotection.	 Likewise,	 regulation	
of	 astrocytic	 metabolism	 and	 prevention	 of	 astrocytic	 apoptosis	 against	 oxidative	
stress	 is	 decisive	 for	 the	 brain	 homeostasis	 maintenance.	 Indeed,	 CO	 gas	 limited	
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astrocytic	 apoptosis	 by	 two	 distinct	 ways:	 (i)	 direct	 prevention	 of	 mitochondrial	
membrane	 permeabilisation	 and	 the	 consequent	 release	 into	 the	 cytosol	 of	 pro-
apoptotic	factors	(Queiroga	et	al.,	2010)	and	(ii)	improvement	of	cellular	metabolism	
and	increase	on	oxidative	phosphorylation	and	mitochondrial	population	(Almeida	et	
al.,	2012).	
Furthermore,	 excessive	 inflammation	 response	 can	 be	 detrimental,	 being	 CO’s	
modulation	 of	 inflammation	 in	 microglia	 very	 important	 for	 the	 control	 of	
neuroinflammation.	 Many	 studies	 of	 the	 CO	 anti-inflammatory	 effect	 have	 been	
done	 in	 vitro	 using	 BV-2	 microglial	 cells.	 CORM-3	 was	 shown	 by	 Bani-Hani	 and	
colleagues	 to	 decrease	 NO	 production	 and	 TNF-α	 release	 in	 response	 to	 LPS,	
thrombin	and	 INF-γ	 stimulus.	 It	was	described	 that	 inhibition	of	mitogen-activated	
protein	 kinases	 phosphatidyl	 inositol	 3-kinase	 (PI3K)	 exacerbated	 the	 anti-
inflammatory	effect	of	CORM-3.	On	the	opposite,	sGC,	NOS	and	HO	activity	had	no	
influence	 on	 CORM-3	 mode	 of	 action	 (Bani-Hani	 et	 al.,	 2006b,	 Bani-Hani	 et	 al.,	
2006a).	 Taken	 all	 together,	 the	 ability	 of	 CO	 in	 limiting	 inflammatory	 response	
promotes	neuronal	survival	and	is	important	for	CO-induced	neuroprotection.	
Inflammatory	 brain	 disease,	 oxidative	 stress	 or	 excitotoxicity	 (with	 excessive	
glutamate	release)	might	damage	cerebral	vascular	endothelial	cells	leading	to	blood	
flow	dysregulation	and	permeabilization	of	blood	brain	barrier	(BBB).	Parfenova	and	
colleagues	 have	 demonstrated	 that	 in	 cerebral	 microvascular	 endothelial	 cells	
(CMEC)	 present	 HO-1	 and	 HO-2	 isoforms	 and	 their	 endogenous	 CO	 regulates	
vascular	 tone	 in	 response	 to	 glutamate	 (Parfenova	 et	 al.,	 2001,	 Parfenova	 et	 al.,	
2003,	 Leffler	 et	 al.,	 2011).	 Likewise,	 endogenous	 and	 exogenous	 CO	 prevents	
endothelial	cell	death	via	modulation	of	Nox4	NADPH	activity	(Basuroy	et	al.,	2009,	
Basuroy	 et	 al.,	 2011),	 see	 next	 section.	 Finally,	 CORM-A1	 prevents	 blood	 brain	
barrier	dysfunction	by	 limiting	glutamate-induced	apoptosis	and	oxidative	 stress	 in	
CMEC	 (Basuroy	 et	 al.,	 2013).	 Still,	 one	 can	 speculate	 that	 the	 astrocytic	 end-feet	
processes	 and	 perivascular	 neurons	 associated	 with	 BBB	 are	 the	 prime	 targets	 of	
CO’s	effects	in	the	brain.	 
	
Pathways	involved	in	CO	signalling	
Several	pathways	have	been	proposed	in	the	literature	to	contribute	to	the	cellular	
and	 biochemical	 mechanisms	 associated	 with	 CO’s	 biological	 role.	 Yet,	 those	
biochemical	pathways	and	the	actual	physiological	target(s)	of	CO	are	still	a	matter	
of	great	discussion	(Motterlini	and	Otterbein,	2010).	CO	is	a	rather	chemically	 inert	
molecule	 and	 in	biological	 systems	 it	 can	only	bind	 to	 transition	metals	present	 in	
several	 proteins	 (Boczkowski	 et	 al.,	 2006),	 which	 modulate	 their	 activity.	 In	
mammals,	 iron-containing	 haem	 proteins	 are	 the	 most	 studied	 and	 documented	
targets	 for	 CO.	 Notably,	 CO	 can	 only	 bind	 to	 reduced	 Fe2+,	 limiting	 the	 potential	
target	proteins,	 in	contrast	 to	NO	that	binds	both	Fe2+	and	Fe3+	 (Boczkowski	et	al.,	
2006).	
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In	 CNS,	 the	 pathways	 and	 potential	 targets	 of	 CO	 are	 still	 poorly	 understood	with	
few	available	data	on	the	literature	concerning	the	mechanisms	by	which	CO	confers	
neuroprotection,	 anti-neuroinflammation	 or	 vasomodulation,	 being	 urgent	 the	
development	 of	more	 scientific	 research	 on	 this	 subject.	 This	 section	 focuses	 and	
discusses	the	existing	data	about	CO’s	pathways	in	the	brain.	
	
Soluble	Guanylyl	Cyclase	(sGC)	and	Nitric	Oxide	Synthase	(NOS)	
One	 of	 the	 most	 studied	 pathways	 for	 CO	 is	 the	 activation	 of	 sGC	 and	 NOS.	
Nevertheless,	 the	 binding	 affinity	 of	 CO	 for	 sGC	 is	 still	 controversial	 under	
physiological	 conditions,	 since	 high	 concentrations	 of	 CO	 are	 usually	 required	 for	
activating	sGC.	On	the	contrary,	much	lower	NO	levels	are	needed	for	activating	sGC.	
Regarding	neuronal	cells,	activation	of	sGC	and	NOS	and	the	respective	production	
of	 cyclic	 guanosine	monophosphate	 (cGMP)	 and	NO,	were	 shown	 to	be	 important	
for	CO-induced	neuroprotection	against	excitotoxicity	and	 ischemic	 insult	 (Vieira	et	
al.,	 2008,	 Schallner	 et	 al.,	 2013).	 In	 a	 model	 of	 permanent	 ischemic	 stroke,	 the	
protective	role	of	HO-1	is	correlated	with	higher	levels	of	endothelial	NOS	expression	
in	 the	 brain	 (Shah	 et	 al.,	 2011).	 Likewise,	 in	 a	 neuroinflammatory	 model,	 CO	
regulates	inflammation	in	microgial	cells	by	modulating	NO	production	(Bani-Hani	et	
al.,	 2006b,	Bani-Hani	 et	 al.,	 2006a).	 Still,	 increased	 levels	 of	 cGMP	appeared	 to	be	
downstream	to	endogenous	CO	production	in	astrocytes	(Imuta	et	al.,	2007);	while	
in	 cerebral	 microvessels	 cGMP	 signalling	 appeared	 to	 be	 upstream	 of	 CO	
modulation,	 since	 glutamate-induced	 NOS	 activation	 leaded	 to	 CO	 production	 via	
cGMP	signalling	(Leffler	et	al.,	2005).		
Finally,	CO	appears	also	to	modulate	pain	through	NO	signalling.	The	antinociceptive	
effects	 of	morphine	 and	 agonists	 of	 μ-opioid	 receptors	 (MOR),	 δ-opioid	 receptors	
(DOR)	and	cannabinoid-2	receptor	(CB2R) are	improved	by	CO	(CORM-2	and	CORM-
3)	 in	 a	 NO-dependent	 fashion	 during	 chronic	 inflammatory	 and	 neuropathic	 pain	
(Hervera	et	al.,	2013a,	Hervera	et	al.,	2013b). 
	
Reactive	oxygen	species	(ROS)	signalling	
It	is	increasingly	accepted	in	several	cell	and	tissue	models	that	the	mediation	of	CO-
induced	cytoprotection	is	via	ROS	generation	and	signalling	(for	review	(Bilban	et	al.,	
2008,	 Queiroga	 et	 al.,	 2012a).	 At	 least	 two	 cellular	 proteins	 are	 recognized	 to	 be	
directly	 implicated	 in	 cell	 redox	 signalling	 by	 CO:	 cytochrome	 c	 oxidase	
(mitochondrial	respiratory	complex	IV)	and	NAD(P)H	oxidase	(plasmatic	membrane).		
Cytochrome	 c	 oxidase	 is	 the	 main	 described	 target	 for	 the	 CO-cytotoxic	 effects;	
actually	 it	 is	 widely	 accepted	 that	 by	 binding	 to	 cytochrome	 c	 oxidase,	 CO	 blocks	
mitochondrial	 respiration	 promoting	 cell	 death	 (Wainio	 and	 Greenless,	 1960,	
Savolainen	et	al.,	1980,	Alonso	et	al.,	2003).	Furthermore,	endogenous	CO	can	also	
control	 and	 inhibit	 cellular	 respiration	 through	 acting	 on	 cytochrome	 c	 oxidase	
(D'Amico	et	al.,	2006).	 In	neural	cells,	namely	astrocytes,	 low	concentrations	of	CO	
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present	a	two-step	response	regarding	cytochrome	c	oxidase	activity.	During	the	first	
minutes	following	CO	treatment,	there	is	a	slight	decrease	on	cytochrome	c	oxidase	
activity,	 while	 after	 30	 minutes	 (and	 up	 to	 24h)	 specific	 activity	 of	 cytochrome	 c	
oxidase	increases	(Almeida	et	al.,	2012).	Thus,	these	data	indicate	a	direct	action	of	
CO	on	complex	IV	of	mitochondrial	respiratory	chain	and	reinforces	the	hypotheses	
claiming	 that	 ROS	 production	 occurs	 at	 complex	 III	 level	 due	 to	 electron	
accumulation	whenever	 complex	 IV	 is	 inhibited.	 Likewise,	 in	 non-synaptic	 isolated	
mitochondria	from	rat	brain	cortex,	CO	promotes	ROS	generation	(Queiroga	2010);	
and	 the	use	of	β-carotene	 for	 limiting	ROS	 levels	has	prevented	 the	anti-apoptotic	
effect	 of	 CO	 in	 astrocytes,	 as	 well	 as	 the	 CO-induced	 protection	 against	
mitochondrial	membrane	permeabilisation	(Queiroga	et	al.,	2010).	In	primary	culture	
of	 cerebellar	 granular	 neurons,	 small	 amounts	 of	 ROS	 are	 produced	 upon	 CO	
treatment;	and	whenever	ROS	generation	is	prevented	by	butyl-hydroxytoluene,	the	
neuroprotective	 effect	 of	 CO	 is	 reverted,	 indicating	 the	 essential	 role	 of	 ROS	 as	
signalling	factors	(Vieira	et	al.,	2008).		
In	inflammatory	brain	diseases,	NADPH	oxidase,	in	particular	its	major	isoform	Nox4,	
generates	 ROS,	 which	 can	 initiate	 both	 death	 and	 survival	 pathways	 in	 TNF-α-
challenged	 cerebral	 microvascular	 endothelial	 cells	 (CMVEC).	 Endogenous	 and	
exogenous	CO	limits	the	production	of	anion	superoxide	by	Nox4	NADPH,	preventing	
endothelial	cell	death	caused	by	TNF-alpha-induced	oxidative	stress	(Basuroy	et	al.,	
2009).	While,	Nox4	NADPH-derived	reactive	oxygen	species	(ROS)	also	initiate	a	cell	
survival	mechanism	by	increasing	production	of	CO	by	constitutive	HO-2	(Basuroy	et	
al.,	 2011).	 The	 ROS-dependent	 cell	 survival	 pathway	 is	 mediated	 by	 TNF-α,	 Akt,	
ERK1/2,	and	p38	MAPK	signalling	pathways	(Basuroy	et	al.,	2011).	Therefore,	there	
might	 be	 a	 feedback	 control	 of	 ROS	 production	 regulated	 by	 CO,	whereas	NADPH	
oxidase	produces	ROS	that	increase	CO	generation,	which,	in	turn,	prevents	NADPH	
oxidase	activity,	its	excessive	anion	superoxide	production	and	oxidative	stress.	
In	 no-brain	 systems	 there	 are	 other	 potential	 pathways	 for	 biological	 CO	 action	
related	 to	 ROS	 signalling	 and	 mitochondria.	 In	 cardiomyocytes	 CO-induced	
mitochondrial	 ROS	 production	may	 control	 of	mitochondrial	 biogenesis	 leading	 to	
cytoprotection	 (Suliman	 et	 al.,	 2007a,	 Suliman	 et	 al.,	 2007b).	 Likewise,	 in	 isolated	
heart	 mitochondria,	 CORM-3	 limits	 excessive	 mitochondrial	 ROS	 production	 and	
avoids	oxidative	stress	by	inducing	a	mild-uncoupling	state;	while	complex	II	seems	
to	be	CO’s	target	be	since	inhibition	of	complex	II	(malonate	addition)	reverted	the	
CO-induced	 augmentation	 of	 oxygen	 consumption	 and	 the	 uncoupling	 effect	 (Lo	
Iacono	 et	 al.,	 2011).	 In	 contrast,	 in	 liver	 system,	 CO	 has	 been	 described	 as	
cytoprotective	molecule	 by	 targeting	 cytochrome	 P450	 and	 limiting	 excessive	 ROS	
production	 and	 oxidative	 stress-induced	 cell	 death.	 The	 best-described	 example	 is	
the	 isoform	 cytochrome	 P450	 2E1,	 which	 is	 involved	 in	 acetaminophen	
hepatotoxicity	 (Gong	 et	 al.,	 2004).	 Based	 on	 data	 derived	 from	 other	 organs	 and	
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tissues,	neuroscientists	should	explore	other	potential	targets	and	pathways	for	the	
well-accepted	beneficial	effects	of	CO	in	the	brain.	
	
CO	and	potassium	channels	
In	 2003	 it	 was	 shown	 by	 Tang	 and	 colleagues	 that	 large-conductance	 calcium-
dependent	potassium	channels	possess	a	conserved	haem-binding	sequence	motif,	
which	can	bind	covalently	to	haem,	regulating	its	channel	activity	(Tang	et	al.,	2003).	
One	 year	 later	 HO-2	 derived	 CO	was	 demonstrated	 to	modulate	 calcium-sensitive	
potassium	(BK)	channels,	which	are	important	for	sensing	oxygen	levels	(Williams	et	
al.,	2004,	Jaggar	et	al.,	2005).	Furthermore,	endogenous	CO	may	modulate	cerebral	
microvasculature	by	activating	calcium-dependent	potassium	channels	(Jaggar	et	al.,	
2005).	 Namely,	 astrocytic	 HO-2-derived	 CO	 causes	 glutamatergic	 dilation	 of	 pial	
arterioles,	by	activating	smooth	muscle	cell	large-conductance	Ca(2+)-activated	K(+)	
(BK(Ca))	channels	(Leffler	et	al.,	2011).	Thus,	one	can	speculate	that	CO	binds	directly	
to	 BK(Ca)	 channel-bound	 haem	 for	 controlling	 dilation	 and	 constriction	 of	
vasculature	(Leffler	et	al.,	2011).	
	
Insert	FIGURE	2	here	
	
	
Future	challenges	for	CO	administration	
The	first	issue	for	the	clinical	potential	use	of	CO	in	cerebral	pathologies	is	the	lack	of	
information	about	 its	mode	of	action.	Despite	 the	described	different	mechanisms	
about	the	cellular	and	biochemical	pathways	of	CO,	the	precise	underlying	signalling	
mechanisms	 and	 the	 exact	 molecular	 target(s)	 of	 CO	 are	 poorly	 elucidated.	 It	 is	
worth	 of	 note	 that	 elucidating	 the	 potential	 protein	 targets	 of	 CO	 under	
physiological	conditions	is	extremely	complex,	since	CO	might	bind	to	its	target	on	a	
dynamic	 and	 transitory	 way.	 Furthermore,	 CO	 directly	 competes	 with	 oxygen	 for	
binding	to	proteins,	thus	tissue	and	cellular	oxygen	levels	also	influence	the	system	
complexity	to	study	CO	targets	under	physiological	conditions.	Based	on	the	fact	that	
CO	seems	to	mimic	preconditioning,	promoting	a	 tissue	tolerance	state,	one	might	
explore	the	classical	activator	and	transducer	factors	involved	in	preconditioning	and	
CO.	 For	 instance,	 preconditioning	 stimulus	 leads	 to	 upregulation	 of	 vascular	
endothelial	 growth	 factor	 (VEGF)	 (Laudenbach	 et	 al.,	 2007,	 Wick	 et	 al.,	 2002),	
activation	of	hypoxic	inducible	factor	(HIF-1)	(Chu	et	al.,	2010,	Ratan	et	al.,	2004)	or	
expression	 of	 erythropoietin	 (Ruscher	 et	 al.,	 2002),	 being	 these	 factors	 promising	
candidates	for	CO	related	pathways.	Indeed,	in	macrophages	CO	has	been	described	
to	stabilize	HIF-1	(Chin	et	al.,	2007).	
	
The	 second	 challenge	 concerning	 CO	 administration	 is	 achieving	 the	 best	 way	 to	
specifically	 deliver	 CO	 in	 the	 target	 tissue,	 avoiding	 high	 concentrations	 of	
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carboxyhaemoglobin.	 Many	 studies	 have	 been	 performed	 for	 developing	 CORMs	
avoiding	systemic	toxicity	related	to	carboxyhaemoglobin,	for	further	review	(Romao	
et	 al.,	 2012,	 Zobi,	 2013).	 Indeed,	 there	 are	 CORMs	 with	 different	 effects	 on	
carboxyhaemoglobin;	 while	 CO	 gas	 exposure	 and	 CORM-A1	 administration	 reach	
similar	levels	of	carboxyhaemoglobin	(Otterbein	et	al.,	1999,	Ryan	et	al.,	2006),	very	
low	 changes	 in	 carboxyhaemoglobin	 levels	 were	 observed	 in	 the	 case	 of	 CORM-3	
(Guo	et	al.,	2004).		Nevertheless,	how	and	where	administrate	CORMs	to	deliver	CO	
is	still	a	matter	of	intensive	research.	Likewise,	chemical	modifications	of	CORMs	are	
under	progress	to	target	these	molecules	to	a	specific	organ/cell	type	(Fagone	et	al.,	
2012).	 	 Up	 to	 date	 the	 best	 example	 concerns	 ALF	 794	 specifically	 targeting	 liver	
against	 acute	 injury	 (Marques	 et	 al.,	 2012).	 Still,	 several	 questions	 remain	
unanswered:	How	CORM	is	transported	in	the	blood	flow?	Does	CORM	bind	to	any	
protein	present	in	the	blood	for	maintaining	its	stability?	Does	CORM	need	to	cross	
the	 cellular	 plasma	membrane?	 Is	 CO	 delivered	 in	 the	 extracellular	 space,	 getting	
intracellularly	by	membrane	diffusion?	Therefore,	 further	studies	are	necessary	 for	
disclosing	 how	 the	 existing	 CORMs	 act	 under	 physiological	 conditions.	 Still,	 the	
development	 of	 new	 molecules	 with	 optimal	 control	 of	 CO	 delivery	 (locus	 and	
kinetics)	 is	 also	 crucial	 for	 the	 progress	 of	 CO	 gasotransmitter	 as	 novel	 drug	 for	
medical	applications.	
Furthermore,	 in	 the	brain,	another	vital	biological	challenge	exists:	 the	blood	brain	
barrier	(BBB).	Several	brain	studies	have	been	performed	in	vivo	using	CORM-3	and	
CORM-A1	 with	 promising	 results.	 Although	 it	 is	 not	 precisely	 verified	 that	 these	
CORMs	 are	 able	 to	 cross	 the	 BBB,	 CO	 does	 enter	 into	 the	 brain	 acting	 as	 a	
cytoprotective	 molecule	 (Zimmermann	 et	 al.,	 2007,	 Parfenova	 et	 al.,	 2012a,	
Yabluchanskiy	et	al.,	2012).	
The	 time	 window	 for	 CO	 administration	 is	 essential	 for	 the	 best	 outcome	 and	
depends	on	the	pathophysiological	situation.	Preconditioning	 is	one	of	 the	claimed	
CO-induced	 processes,	 where	 CO	 stimulates	 endogenous	 cellular	 pathways	 of	
protection	 (anti-inflammatory,	 anti-apoptotic,	 pro-survival,	 pro-homeostatic,	 etc)	
(Bilban	et	al.,	2008,	Queiroga	et	al.,	2012b,	Piantadosi	et	al.,	2008).	In	this	case,	the	
therapeutic	 strategy	 consists	 of	 CO	 administration	 previously	 to	 the	 injury;	 for	
instance	 in	high	 risk	patients	of	developing	cerebral	 ischemia	 (before	great	cardiac	
surgeries,	 high	 risk	 newborn	 infants,	 aging	 patients	 with	 cardiovascular	
complications	and	risk	of	 ischemic	stroke).	Still,	during	the	development	of	chronic	
diseases,	exogenous	CO	can	be	used	as	a	periconditioning	agent,	namely	Alzheimer	
disease,	 Parkinson	 disease	 or	 multiple	 sclerosis	 (Fagone	 et	 al.,	 2011).	 Another	
evidence	in	the	literature	concerns	the	ability	of	CO	to	respond	against	acute	injury,	
thus	CO	can	be	applied	after	injury,	as	postconditioning	strategy,	such	as	described	
in	 cerebral	 ischemia,	 intracerebral	 haemorrhage	 and	 seizures	 (Wang	 et	 al.,	 2011,	
Yabluchanskiy	et	al.,	2012,	Zeynalov	and	Dore,	2009).	
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Final	conclusions	
There	 is	 a	 groundbreaking	 evidence	 supporting	 the	 protective	 role	 of	 carbon	
monoxide	 (and	 haem	 oxygenase)	 in	 the	 central	 nervous	 system	 in	 the	 context	 of	
several	 pathologies:	 cerebrovascular	 diseases,	 neuroinflammation,	 multiple	
sclerosis,	pain,	Alzheimer	and	Parkinson	diseases.	
The	 therapeutic	 advent	 leads	 to	 the	 need	 of	 further	 development	 of	 CO	 sources,	
others	 from	 CO	 gas,	 to	 overcome	 the	 carboxyhaemoglobin	 toxicity.	 CORMs	 have	
been	 increasingly	used	with	successful	and	 interesting	 results.	Nevertheless,	 it	was	
the	inhaled	CO	that	has	been	firstly	proven	to	be	safe	and	tolerable	in	humans.		
Independently	 of	 the	 administration	 route	 and	 regardless	 of	 the	 cell	 type,	 CO	
appears	 to	modulate	 several	 cellular	 players,	 such	 as	 cytochrome	 c	 oxidase,	 nitric	
oxide	 synthase	 (NOS),	 soluble	 guanylyl	 cyclase	 (sGC)	 or	 NADPH	 oxidase;	 ROS	
signaling	 and	 mitochondria	 targeting	 are	 also	 involved	 in	 CO’s	 pathways.	
Nevertheless,	 further	 research	 is	 urgently	 necessary	 for	 precisely	 clarify	 the	
biological	CO	target(s)	and	pathways.	
In	 conclusion,	 carbon	 monoxide	 has	 travelled	 far	 away	 from	 being	 an	 invisible	
enemy,	becoming	a	possible	consistent	therapeutic	solution.		
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